Table 4.

Descriptive and comparative analysis between the four drugs regarding the percentage of injections made, per patient, in periods of 90 days

Drug	n	(%)
		Mean ± SD	Median (Q1–Q3)
Aflibercept	33	49.7 ± 1.4	50.0 (50.0–50.0)
Bevacizumab	32	28.1 ± 19.1	33.3 (8.3–50.0)
Ranibizumab	33	26.3 ± 21.2	25.0 (0.0–50.0)
Ziv-aflibercept	33	30.6 ± 19.2	33.3 (16.7–50.0)
		p < 0.001 (H3 = 34.594; Z = 4.335 and r = 0.75) Aflib > (Beva = Rani = Ziv)

Note: p → Kruskal–Wallis test